Media, investors, advocacy organizations and others, please contact us here.

Publications FSGS

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

View
Publications FSGS

Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden

View
Medical Information FSGS

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 DUPLEX Study Published in the NEJM

Publications FSGS

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

View
Posters FSGS

Long-Term Sparsentan Treatment in FSGS in the DUET Open-Label Extension (OLE)

Posters FSGS

Long-Term Sparsentan Treatment in Young Patients With Focal Segmental Glomerulosclerosis (FSGS) in the DUET Open-Label Extension (OLE)

Posters FSGS

Epidemiology, Patient Journey, and Burden of Focal Segmental Glomerculosclerosis (FSGS): An Analysis of Veteran’s Affairs Data

Posters FSGS

The natural history of FSGS in the German Chronic Kidney Disease (GCKD) cohort

Posters FSGS

Outcomes in SRNS (FSGS) patients in the UK RaDaR Idiopathic Nephrotic Syndrome Registry and their relationship with time-averaged proteinuria

Posters FSGS

Understanding the Impact of Immunoglobulin ANephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS) on Patients and Care-Partners Study(HONUS): Updated Results for IgAN in the United States (US)

Publications FSGS

Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial

View
Medical Information FSGS

EPPIK (Phase 2 Study): Treatment in Pediatric Patients With Proteinuric Glomerular Diseases

Medical Information FSGS

PROTECT (Phase 3 Study): Study Design & Results